BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23539389)

  • 1. 5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
    Berindan-Neagoe I; Braicu C; Pileczki V; Cojocneanu Petric R; Miron N; Balacescu O; Iancu D; Ciuleanu T
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):37-43. PubMed ID: 23539389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
    Gu WJ; Liu HL
    Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
    Subbarayan PR; Lee K; Ardalan B
    Anticancer Res; 2010 Apr; 30(4):1157-62. PubMed ID: 20530422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
    Zhang H; Tang J; Li C; Kong J; Wang J; Wu Y; Xu E; Lai M
    Cancer Lett; 2015 Jan; 356(2 Pt B):781-90. PubMed ID: 25449431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.
    Hwang JT; Ha J; Park OJ
    Biochem Biophys Res Commun; 2005 Jul; 332(2):433-40. PubMed ID: 15896711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R; Tanabe K; Inoue H; Toge T
    Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
    Takara K; Fujita M; Minegaki T; Yamamoto K; Takahashi M; Yokoyama T; Okumura K
    Eur J Pharm Sci; 2012 Feb; 45(3):272-81. PubMed ID: 22155546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide.
    Flis S; Spłwiński J
    Anticancer Res; 2009 Jan; 29(1):435-41. PubMed ID: 19331183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
    Cai Z; Ke J; He X; Yuan R; Chen Y; Wu X; Wang L; Wang J; Lan P; Wu X
    Ann Surg Oncol; 2014 Jan; 21(1):179-88. PubMed ID: 23907312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel.
    Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
    Int J Oncol; 2004 Apr; 24(4):807-13. PubMed ID: 15010816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
    Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.
    Zhou J; Zhou Y; Yin B; Hao W; Zhao L; Ju W; Bai C
    Oncol Rep; 2010 Jan; 23(1):121-8. PubMed ID: 19956872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.
    Fischel JL; Etienne MC; Formento P; Milano G
    Clin Cancer Res; 1998 Oct; 4(10):2529-35. PubMed ID: 9796987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.